Tissuemed raises $9.75 million for product launch:
This article was originally published in Clinica
Executive Summary
UK company Tissuemed has raised £6.5 million ($9.75 million), which it will use towards the European launch of its surgical adhesive product, tissuebond, later this year. The Leeds-based company, which plans to float within the next 18 months, has also received a further £2 million from 3i. Tissuemed believes its product will overcome the drawbacks of surgical sealants and that sales of the product will be significant. The product has been CE-marked as a haemostat, sealant and aid to anastomosis.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.